Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TOPAZ: Zoledronic Acid for Fracture Prevention in Parkinson's Disease
NCT03924414Phase 4Completed
- Sponsor
- California Pacific Medical Center Research Institute
- Start
- Nov 2019
- Primary completion
- Feb 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, triple-blind trial in osteoporosis comparing Zoledronic acid (ZA) with Placebo (2 arms). Primary endpoint: Number of Participants with Clinical Fractures at 5 years. Started Nov 2019; status: completed.
02
Drugs
zoledronic acid
03
Conditions
osteoporosis
Beyond the preview
Go deeper on NCT03924414.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03924414.